89bio, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. We show 22 historical shares outstanding datapoints in our ETNB shares outstanding history coverage, used to compute ETNB market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ETNB market cap history over the course of time is important for investors
interested in comparing ETNB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ETNB versus a peer is one thing; comparing
ETNB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ETNB can fluctuate over the course of history.
With this page we aim to empower investors researching ETNB by allowing them to research the ETNB market cap history. |
Free ETNB Email Alerts:
Video: The Importance of Market Cap
